• Bloomberg


Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc. The deal will add one potential blockbuster in lung cancer and another already on-the-market therapy.

Takeda will pay $24 a share for Ariad, the companies said in a statement Monday, 75 percent more than its Friday close of $13.74. The deal will give it Ariad’s drug brigatinib, an experimental therapy being tested in lung cancer, and Iclusig, which is estimated to have brought in $170.5 million in 2016.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.